Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Results Earnings Conference Call February 28, 2024 4:30 PM ET

Company Participants

Peter Pfreundschuh - Chief Financial Officer

Alfred Sandrock - President and Chief Executive Officer

Todd Carter - Chief Scientific Officer

Conference Call Participants

Jack Allen - Robert W. Baird

Sam Beck - Citigroup

Jay Olson - Oppenheimer & Co.

Ry Forseth - Guggenheim Securities

Phil Nadeau - TD Cowen

Mehdi Goudarzi - Truist Securities

Sumant Kulkarni - Canaccord Genuity Inc.

Operator

Good day. Thank you for standing by. Welcome to the Q4 2023 Voyager Therapeutics Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Peter Pfreundschuh, Chief Financial Officer. Please go ahead.

Peter Pfreundschuh

Thank you. And good afternoon. Joining me on the call today is Dr. Al Sandrock, our CEO, and Dr. Todd Carter, our Chief Scientific Officer.

We issued our Q4 and year-end 2023 financial results press release this afternoon. The press release and 10-K are available on our website.

In a moment, I will turn the call over to Al. Before I do this, I want to remind everyone that, during this call, Voyager representatives may make forward-looking statements as noted in slide 2 of today's deck. These forward-looking statements include future expectations, plans and prospects. All forward-looking statements are inherently uncertain and are subject to risks and uncertainties that may cause actual results to differ materially from those indicated by these forward-looking statements. You are encouraged to review and understand the various material risks and uncertainties facing the company as described in the company's most recent annual report on Form 10-K filed with the SEC this afternoon. All SEC filings are available on the company's website.

Now, it is my pleasure to turn the call over to Al.

Alfred Sandrock

Thank you, Pete. And good afternoon, everyone. Please turn to slide 3. I'd like to start by defining Voyager's position as an emerging leader in neurogenetic medicine.

First, our pipeline. We anticipate having at least four wholly owned and partnered CNS programs in the clinic by the end of 2025, with the potential to generate clinical data in 2025 and 2026. Our most advanced programs are an anti-tau antibody for Alzheimer's disease and our SOD1 gene therapy program for amyotrophic lateral sclerosis, or ALS. I will talk more about both programs in a few minutes.